| Emma Philbrick, PHARMD | |
|
1626 E Harding St, Morrilton, AR 72110-4504 | |
| (501) 354-1700 | |
| Not Available |
| Full Name | Emma Philbrick |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1626 E Harding St, Morrilton, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154109957 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PD16667 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Emma Philbrick, PHARMD 4710 Sam Peck Rd Apt 1175, Little Rock, AR 72223-5014 Ph: (405) 845-9595 | Emma Philbrick, PHARMD 1626 E Harding St, Morrilton, AR 72110-4504 Ph: (501) 354-1700 |
News Archive
A new study led by scientists at the University of Pennsylvania School of Veterinary Medicine has painted a clearer picture of the delicate arms race between the human immune system and a pathogen that seeks to infect and kill human cells.
A new study produced by an interdisciplinary team led by Prof. Antonio Giordano, director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University, tracks the development process and efficacy of the Italian translation of the Derriford Appearance Scale 24, an important clinical tool in identifying quality-of-life issues for breast cancer patients, especially concerns regarding body shame, depression, anxiety, overall appearance and appearance identity.
A researcher from The University of Texas Medical Branch at Galveston is an integral member of a collaborative group that is the first to explain the mechanisms that the Dengue virus has developed to optimize its ability to cause outbreaks as it travels across the globe to new places and revisits old ones.
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
TORONTO, ON - Professor Frances Jamieson at the University of Toronto's Department of Laboratory Medicine and Pathobiology (LMP), and Medical Microbiologist, Public Health Ontario, is leading the way in tracking potentially deadly outbreaks of tuberculosis (TB) with a powerful new Geographic Information System (GIS) application, known as Ontario Universal Typing - Tuberculosis (OUT-TB) Web.
› Verified 9 days ago
James Seal, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 601 N Saint Joseph St, Morrilton, AR 72110 Phone: 501-354-4669 | |
Rhonda Beck, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1621 N Business 9, Morrilton, AR 72110 Phone: 501-208-6985 | |
Karen Elaine Cree, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 10 Hospital Drive, Morrilton, AR 72110 Phone: 501-354-1460 Fax: 501-354-9724 | |
Jo Claire Hutchison, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 410 S Division St, Morrilton, AR 72110 Phone: 501-354-1213 | |
Andrea Hoggard, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 10 Hospital Dr, Morrilton, AR 72110 Phone: 501-354-1460 | |
Dr. Johanna Rippy, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1621 N Business 9, Morrilton, AR 72110 Phone: 501-354-4135 |